Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling

被引:62
作者
Altinok, Atilla [1 ]
Levi, Francis [2 ,3 ,4 ]
Goldbeter, Albert [1 ]
机构
[1] Univ Libre Bruxelles, Fac Sci, Unite Chronobiol Theor, B-1050 Brussels, Belgium
[2] INSERM, U776, F-94807 Villejuif, France
[3] Univ Paris Sud, UMR S0776, F-91405 Orsay, France
[4] Hop Paul Brousse, AP HP, Dept Cancerol, Unite Chronotherapie, F-94807 Villejuif, France
关键词
Circadian Rhythms; Glutathione; Chronotolerance; Cell Cycle; Cancer Chronotherapy; Model; DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; CIRCADIAN-RHYTHM; FOLINIC ACID; PLASMA-CONCENTRATION; POSSIBLE RELEVANCE; ENZYME-ACTIVITY; MOUSE-LIVER; CLOCKS; TOXICITY; DELIVERY;
D O I
10.1016/j.ejps.2008.10.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We use an automaton model for the cell cycle to assess the toxicity of various circadian patterns of anticancer drug delivery so as to enhance the efficiency of cancer chronotherapy. Based on the sequential transitions between the successive phases G1, S (DNA replication), G2, and M (mitosis) of the cell cycle, the model allows us to simulate the distribution of cell cycle phases as well as entrainment by the circadian clock. We use the model to evaluate circadian patterns of administration of two anticancer drugs, S-fluorouracil (5-FU) and oxaliplatin (l-OHP). We first consider the case of 5-FU, which exerts its cytotoxic effects on cells in S phase. We compare various circadian patterns of drug administration differing by the time of maximum drug delivery. The model explains why minimum cytotoxicity is obtained when the time of peak delivery is close to 4 a.m., which temporal pattern of drug administration is used clinically for 5-FU. We also determine how cytotoxicity is affected by the variability in duration of cell cycle phases and by cell cycle length in the presence or absence of entrainment by the circadian clock. The results indicate that the same temporal pattern of drug administration can have minimum cytotoxicity toward one cell population, e.g. of normal cells, and at the same time can display high cytotoxicity toward a second cell population, e.g. of tumour cells. Thus the model allows us to uncover factors that may contribute to improve simultaneously chronotolerance and chronoefficacy of anticancer drugs. We next consider the case of oxaliplatin, which, in contrast to 5-FU, kills cells in different phases of the cell cycle. We incorporate into the model the pharmacokinetics of plasma thiols and intracellular glutathione, which interfere with the action of the drug by forming with it inactive complexes. The model shows how circadian changes in l-OHP cytotoxicity may arise from circadian variations in the levels of plasma thiols and glutathione. Corroborating experimental and clinical results, the simulations of the model account for the observation that the temporal profiles minimizing l-OHP cytotoxicity are in antiphase with those minimizing cytotoxicity for 5-FU. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:20 / 38
页数:19
相关论文
共 54 条
  • [1] ALTINOK A, 2007, BIOSIMULATION DRUG D, P275
  • [2] A cell cycle automaton model for probing circadian patterns of anticancer drug delivery
    Altinok, Atilla
    Levi, Francis
    Goldbeter, Albert
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (9-10) : 1036 - 1053
  • [3] Circadian expression of clock genes in human oral mucosa and skin : Association with specific cell-cycle phases
    Bjarnason, GA
    Jordan, RCK
    Wood, PA
    Li, Q
    Lincoln, DW
    Sothern, RB
    Hrushesky, WJM
    Ben-David, Y
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (05) : 1793 - 1801
  • [4] Bjarnason GA, 2000, PROG CELL CYC RES, V4, P193
  • [5] BOUGHATTAS NA, 1989, CANCER RES, V49, P3362
  • [6] CIRCADIAN-RHYTHM OF WHITE BLOOD-CELL AGGREGATION AND FREE-RADICAL STATUS IN HEALTHY-VOLUNTEERS
    BRIDGES, AB
    FISHER, TC
    SCOTT, N
    MCLAREN, M
    BELCH, JJF
    [J]. FREE RADICAL RESEARCH COMMUNICATIONS, 1992, 16 (02): : 89 - 97
  • [7] MAMMALIAN-CELL CYCLES NEED 2 RANDOM TRANSITIONS
    BROOKS, RF
    BENNETT, DC
    SMITH, JA
    [J]. CELL, 1980, 19 (02) : 493 - 504
  • [8] BURNS ER, 1984, PHARMACOLOGY, V28, P296
  • [9] Transition probability cell cycle model .1. Balanced growth
    Cain, SJ
    Chau, PC
    [J]. JOURNAL OF THEORETICAL BIOLOGY, 1997, 185 (01) : 55 - 67
  • [10] Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance
    Clairambault, Jean
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (9-10) : 1054 - 1068